FREELINE THERAPEUTICS HOLDIN (FRLN) Stock Analyst Earnings Estimates
NASDAQ:FRLN - Nasdaq - US35655L2060 - ADR - Currency: USD
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A -100.00% | N/A | N/A 190.69% | N/A 55.12% | N/A 13.00% | N/A 150.93% | N/A 16.53% | ||||||
| EBITDA YoY % growth | -40.01M | -62.1M -55.21% | -100.54M -61.90% | -137.61M -36.87% | -95.12M 30.88% | N/A 8.84% | N/A 77.34% | N/A 183.35% | N/A 23.93% | N/A 33.67% | N/A 22.56% | N/A | N/A | |
| EBIT YoY % growth | -40.98M | -63.64M -55.30% | -102.45M -60.98% | -140M -36.65% | -96.86M 30.81% | N/A 24.56% | N/A 71.13% | N/A 169.79% | N/A 24.04% | N/A 37.43% | N/A 24.39% | N/A 283.54% | N/A 36.05% | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | N/A | N/A | -17.36 65.82% | -25.95 -49.48% | N/A 97.48% | N/A -1,214.84% | N/A 135.65% | N/A -150.67% | N/A 3.95% | N/A 88.36% | N/A 167.65% | N/A 452.17% |
All data in USD
| Q4 / 23 | Q1 / 24 | Q2 / 24 | Q3 / 24 | Q4 / 24 | |
|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.18 97.89% | -0.17 96.02% | -0.13 96.81% | -0.15 34.78% | -0.16 11.11% |
| Revenue Q2Q % growth | -100.00% | -100.00% | |||
| EBITDA Q2Q % growth | -16.218M 2.01% | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -14.535M 20.53% | -12.24M 35.37% | -13.158M 25.83% | -14.688M -20.36% | -16.626M -14.39% |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q3 2023 Q2Q % growth | 92.18% | -0.23 | % | |
| Q2 2023 Q2Q % growth | -4.16 13.33% | -3.20 | -0.96 | -29.89% |
| Q1 2023 Q2Q % growth | -4.36 53.86% | -3.16 | -1.20 | -37.89% |
| Q4 2022 Q2Q % growth | -8.70 39.58% | -4.35 | -4.35 | -100.22% |
| Q3 2022 Q2Q % growth | -3.00 -248.84% | -6.78 | 3.78 | 55.77% |
| Q2 2022 Q2Q % growth | -4.80 -328.57% | -7.75 | 2.95 | 38.08% |
| Q1 2022 Q2Q % growth | -9.45 -864.29% | -9.26 | -0.19 | -2.09% |
| Q4 2021 Q2Q % growth | -14.40 -1,536.36% | -10.40 | -4.00 | -38.41% |
| Q3 2021 Q2Q % growth | -0.86 -17.10% | -1.03 | 0.17 | 16.80% |
| Q2 2021 Q2Q % growth | -1.12 65.25% | -0.99 | -0.13 | -13.40% |
| Q1 2021 Q2Q % growth | -0.98 67.10% | -0.80 | -0.18 | -22.78% |
| Q4 2020 Q2Q % growth | -0.88 | -0.72 | -0.16 | -22.38% |
| Period | Reported | Estimate | Difference | Surprise |
|---|
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 0% | 90.94% | 0% | -8.47% |
| Revenue | N/A | N/A | 0% | N/A |